What Pharma Leaders Really Think About AI, RWD & Inclusion
Leaders have high hopes ahead, but key barriers could hold them back. Here’s how to overcome them.
Access the Survey Insights Transforming Biopharma Strategy
Pharma’s AI and RWD Revolution: Breaking Barriers to Growth
This TriNetX exclusive survey report reveals how 150 senior pharmaceutical and biotech executives are leveraging artificial intelligence, real-world data (RWD), and diversity in clinical trials to drive innovation—while navigating persistent challenges.
As the industry faces pressure to modernize drug development and meet evolving regulatory expectations, understanding how leaders are approaching these trends is essential.
Key themes explored in the report include:
- The increasing role of RWD in trial design and regulatory submissions
- Executive concerns over data interoperability and security
- Progress and uncertainty in advancing diversity and inclusion
- The growing role of AI in streamlining trial planning and analysis
Top findings include:
- 77% of executives use RWD in drug development, yet cite data compatibility as the top barrier
- 99% plan to continue or expand inclusion in clinical trials, despite regulatory uncertainty
- 100% agree that real-world evidence can improve regulatory submissions
This report features expert commentary from TriNetX leaders and actionable insights for overcoming common roadblocks.
Submit your details via the form and download the report for free.
Access and Analyze Rich, Secure, Real-Time Data
TriNetX is a global network of healthcare organizations and life science companies, driving real-world research to accelerate the development of life-saving therapies.
From trial operations to evidence generation, we put you at the forefront of discovery.
Clinical Trial Design & Optimization
Datasets & Analytics
Non-US Oncology
Real-World Evidence Generation
Pharmacovigilance & Drug Safety